Day: March 23, 2022

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1148-79-4,2,2′:6′,2”-Terpyridine,as a common compound, the synthetic route is as follows.

Solid [Co(H2O)6](ClO4)2 (10.0 mg, 21.8 lmol) was placed at thebottom of a 4.0 cm3 test tube with 0.50 cm3 of dmso. Then the tubewas slowly filled with 2.50 cm3 of a dmso?CH3OH mixture (1:4 v/v)containing terpy (15.0 mg, 64.4 lmol). Finally, 1 (15.0 mg,9.01 lmol) dissolved in 0.50 cm3 of CH3OH was placed on the topand the tube covered with parafilm. X-ray quality deep browncrystals of 2 were grown in the text tube by slow diffusion at roomtemperature during 25 days. Yield: 3.20 mg (1.30 lmol, 29percent). X-rayabsorption microanalysis for 2: 3:2 Co/Nb molar ratio. Elementalanalysis for C105H86N18O33Co3Nb2 (2490.52 g mol1) ? Exp. (Calc.):percentC 51.55 (50.94), percentH 3.02 (3.18), percentN 10.49 (10.32), percentCo 7.50 (7.30)percent.IR (KBr disk/cm1): 3475 [m(O?H)], 3062 and 2930 [m(C?H)], 1715and 1687 [mas(CO)], 1641 [m(CN)], 1470 and 1448 [m(CC)],1401 [ms(CO)], 905 [m(NbO] and 421 [m(CoAN)].

1148-79-4, The synthetic route of 1148-79-4 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Oliveira, Willian X.C.; Pereira, Cynthia L.M.; Pinheiro, Carlos B.; Krambrock, Klaus; Grancha, Thais; Moliner, Nicolas; Lloret, Francesc; Julve, Miguel; Polyhedron; vol. 117; (2016); p. 710 – 717;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.22348-32-9,(R)-Diphenyl(pyrrolidin-2-yl)methanol,as a common compound, the synthetic route is as follows.

To (S)-diphenylprolinol (4.00 g, 15.8 mmol, 1.00 equiv) in CH2-Cl2 (40 mL) was added imidazole (3.22 g, 47.4 mmol, 3.00 equiv)at 0 C. TMSCl (5.00 mL, 39.5 mmol, 2.50 equiv) was added dropwiseand the reaction was stirred for 12 h at rt. MTBE (100 mL)was added to the reaction and the mixture was filtered. Theorganic phase was washed with H2O (50 mL) and saturated aqueousNaCl (2 50 mL), dried over MgSO4, filtered and concentratedunder reduced pressure to a colorless oil 11 (5.00 g, 15.3 mmol,97%). 1H NMR (400 MHz, CDCl3) d 7.54-7.46 (m, 2H), 7.42-7.36(m, 2H), 7.35-7.20 (m, 6H), 4.07 (t, J = 7.4 Hz, 1H), 2.98-2.75 (m,2H), 1.84-1.72 (m, 1H), 1.68-1.55 (m, 3H), 1.48-1.37 (m, 1H),0.06 (s, 9H) ppm. 13C NMR (101 MHz, CDCl3) d 146.83, 145.78,128.44, 127.61, 127.57, 127.53, 126.90, 126.73, 83.17, 65.42,47.16, 27.51, 25.06, 2.20 ppm. HR-MS (ESI): calculated for (C20H28-NOSi) [M+H]+: 326.1935, found: 326.1937.

22348-32-9, As the paragraph descriping shows that 22348-32-9 is playing an increasingly important role.

Reference：
Article; Murar, Claudia E.; Harmand, Thibault J.; Bode, Jeffrey W.; Bioorganic and Medicinal Chemistry; vol. 25; 18; (2017); p. 4996 – 5001;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.71071-46-0,Dimethyl [2,2′-bipyridine]-4,4′-dicarboxylate,as a common compound, the synthetic route is as follows.

71071-46-0, General procedure: A solution of cis-RuII(bpz)2Cl2 (100 mg, 0.205 mmol) and AgNO3 (77 mg, 0.453 mol) in water (25 mL) was heated at reflux for 48 h. After cooling to room temperature, the mixture was filtered through Celite to remove AgCl, and the filtrate was evaporated to dryness. The residue was dissolved in DMF (15 mL) and the solution purged with argon for 15 min. 4,4?-bis(trifluoromethyl)-2,2?-bipyridyl (121 mg, 0.414 mmol) was added and the mixture heated at 100 °C for 24 h under argon. After cooling to room temperature, the solution was evaporated under vacuum to a small volume and diethyl ether (150 mL) added. The precipitate was filtered off and dissolved in a minimum of cold water to which solid NH4PF6 was added. The solid was filtered off and purified by column chromatography as for 1 to give an orange solid. Yield: 73 mg (35percent).

The synthetic route of 71071-46-0 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Coe, Benjamin J.; Peers, Martyn K.; Scrutton, Nigel S.; Polyhedron; vol. 96; (2015); p. 57 – 65;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

22348-32-9, (R)-Diphenyl(pyrrolidin-2-yl)methanol is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Step 3A. Preparation of TMS-prolinolTo a mixture of prolinol (10.0 g, 39.5 mmol) and imidazole (4.57 g, 67.1 mmol) in THF (100 mL) was added chlorotrimethylsilane (5.57 g, 51.3 mmol) over 15 min while maintaining the batch temperature below 30 0C. The resulting slurry was aged at 50 0C for 3-5 h. The reaction mixture was cooled to ambient tempearture and quenched by addition of MTBE (50 mL) and 15% aq NaCl (100 mL). The organic layer was washed with 15% aq NaCl (50 mL). The solution was azeotropically dried at the constant volume by feeding THF.HPLC MethodColumn: Ascentis Express Cl 8 (100×4.6mm, 2.7um)Column temperature: 45 0CFlow rate: 1.5 ml/minDetection: UV at 210nmGradient:Time(min) 0.1% H^PO4 (0A) MeCN (0A)0 95 51 95 512 10 90Retention times (minutes): prolinol (4.8 min); TMS prolinol (7.3 min), 22348-32-9

The synthetic route of 22348-32-9 has been constantly updated, and we look forward to future research findings.

Reference：
Patent; MERCK SHARP &; DOHME CORP.; XU, Feng; DESMOND, Richard; HOERRNER, R. Scott; HUMPHREY, Guy, R.; ITOH, Tetsuji; JOURNET, Michel; YOSHIKAWA, Naoki; ZACUTO, Michael, J.; WO2010/144293; (2010); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.63-91-2,L-Phenylalanine,as a common compound, the synthetic route is as follows.

63-91-2, The commercially available raw materials L-phenylalanine (LOBA,99%) and D-methionine (LOBA, 99%) in the purest form were taken in an equimolar (1:1) ratio and dissolved in the double distilled water. After continuous stirring for 8 h at room temperature homogenous saturated solution was obtained which was then filtered in the vessel using whatman filter paper at room temperature. After a time span of30 days optically good quality crystals were harvested from the mother solution by solution evaporation method.

As the paragraph descriping shows that 63-91-2 is playing an increasingly important role.

Reference：
Article; Sangeetha; Jayaprakash; Nageshwari; Rathika Thaya Kumari; Sudha; Prakash; Vinitha; Lydia Caroline; Physica B: Condensed Matter; vol. 525; (2017); p. 164 – 174;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1148-79-4,2,2′:6′,2”-Terpyridine,as a common compound, the synthetic route is as follows.

Solid [Co(H2O)6](ClO4)2 (10.0 mg, 21.8 lmol) was placed at thebottom of a 4.0 cm3 test tube with 0.50 cm3 of dmso. Then the tubewas slowly filled with 2.50 cm3 of a dmso?CH3OH mixture (1:4 v/v)containing terpy (15.0 mg, 64.4 lmol). Finally, 1 (15.0 mg,9.01 lmol) dissolved in 0.50 cm3 of CH3OH was placed on the topand the tube covered with parafilm. X-ray quality deep browncrystals of 2 were grown in the text tube by slow diffusion at roomtemperature during 25 days. Yield: 3.20 mg (1.30 lmol, 29percent). X-rayabsorption microanalysis for 2: 3:2 Co/Nb molar ratio. Elementalanalysis for C105H86N18O33Co3Nb2 (2490.52 g mol1) ? Exp. (Calc.):percentC 51.55 (50.94), percentH 3.02 (3.18), percentN 10.49 (10.32), percentCo 7.50 (7.30)percent.IR (KBr disk/cm1): 3475 [m(O?H)], 3062 and 2930 [m(C?H)], 1715and 1687 [mas(CO)], 1641 [m(CN)], 1470 and 1448 [m(CC)],1401 [ms(CO)], 905 [m(NbO] and 421 [m(CoAN)].

1148-79-4, The synthetic route of 1148-79-4 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Oliveira, Willian X.C.; Pereira, Cynthia L.M.; Pinheiro, Carlos B.; Krambrock, Klaus; Grancha, Thais; Moliner, Nicolas; Lloret, Francesc; Julve, Miguel; Polyhedron; vol. 117; (2016); p. 710 – 717;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.22348-32-9,(R)-Diphenyl(pyrrolidin-2-yl)methanol,as a common compound, the synthetic route is as follows.

A solution of (S)-(-)-alpha,alpha-diphenyl-2-pyrrolidinemethanol (240 mg, 0.97 mmol) and 2 M Borane-Dimethylsulfide complex (in THF, 3.4 mL, 6.8 mmol) in dry THF (50 mL) was stirred at rt under N2 for 16 h. A solution of 5-(4-Fluoro-phenyl)-3-oxo-pentanoic acid ethyl ester (2.03 g, 8.57 mmol) in dry THF (20 mL) was then added dropwise at rt over a period of 1 h. The resultant clear solution was stirred at rt for another 35 min and was then cooled to 0 C. in an ice bath. The reaction was quenched by the addition of EtOH (40 mL) and was concentrated under reduced pressure. The residue was taken up with EtOAc (100 mL) and washed successively with H2O (50 mL), 5% NaHCO3 (50 mL), brine (50 mL), and then dried over Na2SO4. Removal of the solvent afforded an oil, which was purified by flush column chromatography on silica gel. The intermediate S-5-(4-Fluoro-phenyl)-3-hydroxy-pentanoic acid ethyl ester was obtained as a colorless oil (1.33 g, 65%). 1H NMR (300 MHz, CDCl3) delta1.25 (t, 3H, J=7), 1.6-1.9 (m, 2H), 2.35-2.50 (m, 2H), 2.60-2.85 (m, 2H), 3.1 (d, 1H, J=5), 3.95-4.05 (m, 1H), 4.1-4.25 (m, 2H), 6.9-7.0 (m, 2H), 7.05-7.2 (m, 2H). ESMS calcd (C13H17FO3): 240.1; found: 241.1 (M+H)+.

22348-32-9, 22348-32-9 (R)-Diphenyl(pyrrolidin-2-yl)methanol 7045371, acatalyst-ligand compound, is more and more widely used in various fields.

Reference：
Patent; Chen, Shoujun; Sun, Lijun; McCleary, Joel; US2003/60633; (2003); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1148-79-4,2,2′:6′,2”-Terpyridine,as a common compound, the synthetic route is as follows.

UO2Cl4?·(H2terpy)2?·2Cl (2): A mixture of 1.7 ml (0.2 mmol) UCl4/HCl 0.12 M, 93 mg (0.4 mmol) 2,2???:6???,2???-terpyridine and 3.3 ml (63 mmol) acetonitrile was placed in a Parr vessel and then heated statically at 120 ?°C for 48 h. The resulting yellow product was then filtered off, washed with water and dried at room temperature (reaction yield 69percent). XRD powder pattern indicated that the compound was obtained as a pure phase (Supplementary Information S3)., 1148-79-4

1148-79-4 2,2′:6′,2”-Terpyridine 70848, acatalyst-ligand compound, is more and more widely used in various fields.

Reference：
Article; Lhoste, Jerome; Henry, Natacha; Loiseau, Thierry; Guyot, Yannick; Abraham, Francis; Polyhedron; vol. 50; 1; (2013); p. 321 – 327;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.22348-32-9,(R)-Diphenyl(pyrrolidin-2-yl)methanol,as a common compound, the synthetic route is as follows.

To (S)-diphenylprolinol (4.00 g, 15.8 mmol, 1.00 equiv) in CH2-Cl2 (40 mL) was added imidazole (3.22 g, 47.4 mmol, 3.00 equiv)at 0 C. TMSCl (5.00 mL, 39.5 mmol, 2.50 equiv) was added dropwiseand the reaction was stirred for 12 h at rt. MTBE (100 mL)was added to the reaction and the mixture was filtered. Theorganic phase was washed with H2O (50 mL) and saturated aqueousNaCl (2 50 mL), dried over MgSO4, filtered and concentratedunder reduced pressure to a colorless oil 11 (5.00 g, 15.3 mmol,97%). 1H NMR (400 MHz, CDCl3) d 7.54-7.46 (m, 2H), 7.42-7.36(m, 2H), 7.35-7.20 (m, 6H), 4.07 (t, J = 7.4 Hz, 1H), 2.98-2.75 (m,2H), 1.84-1.72 (m, 1H), 1.68-1.55 (m, 3H), 1.48-1.37 (m, 1H),0.06 (s, 9H) ppm. 13C NMR (101 MHz, CDCl3) d 146.83, 145.78,128.44, 127.61, 127.57, 127.53, 126.90, 126.73, 83.17, 65.42,47.16, 27.51, 25.06, 2.20 ppm. HR-MS (ESI): calculated for (C20H28-NOSi) [M+H]+: 326.1935, found: 326.1937.

22348-32-9, As the paragraph descriping shows that 22348-32-9 is playing an increasingly important role.

Reference：
Article; Murar, Claudia E.; Harmand, Thibault J.; Bode, Jeffrey W.; Bioorganic and Medicinal Chemistry; vol. 25; 18; (2017); p. 4996 – 5001;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

5144-89-8, 1,10-Phenanthroline hydrate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example I 2,9-bis(4methylphenyl)-1,10-phenanthroline (2). A 1.7 M solution of t-butyllithium in pentane (300 mL, 0.510 mol) was added under argon to a stirred suspension of p-iodotoluene (56.04 g, 0.257 mol) in ether (150 mL) at -78 C. The mixture was allowed to warm to room temperature over 1 h. The resulting solution of tolyllithium was added to a solution of 1,10-phenanthroline monohydrate (8.50 g, 0.043 mol) in toluene (100 mL). The resulting dark red solution was stirred under argon for 48 h. The reaction was carefully quenched with water (300 mL) and extracted with CH2 Cl2 (3*150 mL). The combined organic layers were dried (Na2 SO4) and evaporated to a volume of 500 mL under reduced pressure. The solution of crude product was oxidized by stirring with activated MnO2 (60 g). An additional portion of MnO2 (30 g) was added to the reaction after 1 h to ensure complete oxidation. After a total of 2 h, anhydrous MgSO4 (40 g) was added, and the mixture was filtered. The MnO2 /MgSO4 was washed with CH2 Cl2 (300 mL), and the solvent was concentrated to a volume of 50 mL, when a crystalline solid formed. The solution was cooled in ice and filtered. The light yellow product crystals were filtered, washed with one portion of cold toluene (20 mL), and dried. Yield 8.63 g 56%). 1 H NMR (CDCl3) delta8.38 (d, J=8.1 Hz, 4H), 8.29 (d, J=8.5 Hz, 2H), 8.13 (d, J=8.4 Hz, 2H), 7.77 (s, 2H), 7.40 (d, J=8.1 Hz, 4H), 2.47 (s, 6H)., 5144-89-8

As the paragraph descriping shows that 5144-89-8 is playing an increasingly important role.

Reference：
Patent; University of Pittsburgh of the Commonwealth System of Higher Education; US5998594; (1999); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI